Trial Profile
A retrospective cohort study to evaluate the incidence of major bleeding in patients receiving ibrutinib concomitantly with antiplatelet agents
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jan 2017
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Antiplatelets
- Indications Chronic lymphocytic leukaemia; Macroglobulinaemia; Mantle-cell lymphoma
- Focus Adverse reactions
- 19 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology